Safety, efficacy, and reliability evaluation ofa novel small-diameter defibrillation lead: Global LEADR pivotal trial results.
Publication/Presentation Date
5-17-2024
Abstract
BACKGROUND: Implantable cardioverter-defibrillators last longer, and interest in reliable leads with targeted lead placement is growing. The OmniaSecure defibrillation lead is a novel, small-diameter, catheter-delivered lead designed for targeted placement, based on the established SelectSecure SureScan MRI Model 3830 lumenless pacing lead platform.
OBJECTIVE: This trial assessed safety and efficacy of the OmniaSecure defibrillation lead.
METHODS: The worldwide LEADR pivotal clinical trial enrolled patients indicated for de novo implantation of a primary or secondary prevention implantable cardioverter-defibrillator or cardiac resynchronization therapy defibrillator, all of whom received the study lead. The primary efficacy end point was successful defibrillation at implantation per protocol. The primary safety end point was freedom from study lead-related major complications at 6 months. The primary efficacy and safety objectives were met if the lower bound of the 2-sided 95% credible interval was >88% and >90%, respectively.
RESULTS: In total, 643 patients successfully received the study lead, and 505 patients have completed 12-month follow-up. The lead was placed in the desired right ventricular location in 99.5% of patients. Defibrillation testing at implantation was completed in 119 patients, with success in 97.5%. The Kaplan-Meier estimated freedom from study lead-related major complications was 97.1% at 6 and 12 months. The trial exceeded the primary efficacy and safety objective thresholds. There were zero study lead fractures and electrical performance was stable throughout the mean follow-up of 12.7 ± 4.8 months (mean ± SD).
CONCLUSION: The OmniaSecure lead exceeded prespecified primary end point performance goals for safety and efficacy, demonstrating high defibrillation success and a low occurrence of lead-related major complications with zero lead fractures.
ISSN
1556-3871
Published In/Presented At
Crossley, G. H., 3rd, Sanders, P., Hansky, B., De Filippo, P., Shah, M. J., Shoda, M., Khelae, S. K., Richardson, T. D., Philippon, F., Zakaib, J. S., Tse, H. F., Sholevar, D. P., Stellbrink, C., Pathak, R. K., Milašinović, G., Chinitz, J. S., Tsang, B., West, M. B., Ramza, B. M., Han, X., … Lead EvaluAtion for Defibrillation and Reliability Trial Investigators (2024). Safety, efficacy, and reliability evaluation ofa novel small-diameter defibrillation lead: Global LEADR pivotal trial results. Heart rhythm, S1547-5271(24)02395-6. Advance online publication. https://doi.org/10.1016/j.hrthm.2024.04.067
Disciplines
Medicine and Health Sciences
PubMedID
38762820
Department(s)
Department of Medicine
Document Type
Article